Clotrimazole vs. Mycelex® in Patients With Human Insufficiency Virus (HIV) Infection for the Treatment of Oropharyngeal Candidiasis

Inclusion Criteria:

• Documented HIV positive status

• Clinical examination of oropharynx is consistent with diagnosis of oral Candidiasis (such as creamy, white, curdlike patches or erythematous lesions on mucosal surfaces)

• Findings on direct microscopic examination (Gram Stain or potassium hydroxide smear)consistent with Candida species or positive fungal culture for Candida species, withculture obtained in the 2 days preceding initiation of therapy with the study drug

• Male or female patients ≥ 18 years

• For women of childbearing potential: negative blood or urine pregnancy test andagreement to use adequate contraception (investigator's discretion) while on studydrug

• Mental status allows comprehension of instructions for troche administration

• Written informed consent

Exclusion Criteria:

• Sings of symptoms suggestive of esophageal Candidiasis (such as dysphagia orodynophagia) unless the results of an endoscopic evaluation of the esophagus arenegative

• Presence of perioral lesions only

• Use of other antifungal agents within 5 days of enrollment to the study

• Pregnant or lactating women

• History of hypersensitivity to imidazole or azole compounds

• Patient unwilling or unable to be followed at the study center for the duration of thestudy (3 weeks)

• Patients has received an investigational drug in the last 30 days

• Treatment with another investigational drug is planned within the next 3 weeks